Skip to main content
Premium Trial:

Request an Annual Quote

Edward Albini, Susan Berland, Stephen Read, John McCarthy, Debra Hutson, Steve Owings, Clive Seymour, James Lewkowski, Gregory Sloma, Eric Topol


Lynx Therapeutics said its CFO, Edward Albini, has resigned “to pursue another opportunity.” Susan Berland, a consultant that has worked with Lynx since before Albini’s departure, will become acting CFO until the company finds a replacement. Before consulting for Lynx, Berland was CFO at DNA Sciences for three years.

Stephen Read has become interim CFO of Exact Sciences, replacing John McCarthy, who left the company “to pursue other opportunities,” Exact Sciences said this week. Exact is currently looking for a permanent replacement for McCarthy, who joined the company in 2000.

Epoch Biosciences has filled two new senior-management positions in its diagnostic business: Debra Hutson was named as director of quality assurance, and is responsible for bringing Epoch’s manufacturing operations into cGMP compliance for the manufacture of analyte-specific reagents; Steve Owings joined Epoch, and has become director of business development for the diagnostics business.

Hutson was formerly director for quality assurance of manufacturing at CombiMatrix, and had stints at Sterling and DuPont. Owings was vice president of sales and marketing at Visible Genetics, which was acquired by Bayer Diagnostics in 2002. He also worked with Digene and Roche Diagnostics, where he was director of the PCR business unit. (See page 1 for information on Epoch’s new business directions, and SNIPPETS, page 7, for information on Epoch’s fourth-quarter earnings.)

Bruker Daltonics has hired Clive Seymour to be vice president for Asia-Pacific. Seymour, who began his new job March 1, is responsible for managing sales and marketing and various customer-service and support operations in the countries the company covers in the Asia-Pacific region, which include Australia, China and Hong Kong, Singapore, Malaysia, Thailand, Vietnam, Laos, Cambodia, the Philippines, Indonesia, and Taiwan. Seymour will also oversee distribution channels in South Korea and New Zealand.

Seymour comes to Bruker from Biacore, where he was vice president for the Asia-Pacific region. He has also been European market area manager for Pharmacia Biotech Europe, and regional marketing and sales manager for Pharmacia Biotech Asia Pacific, according to Bruker.

James Lewkowski has become executive vice president for Annapolis, Md.-based PharmAthene, the company said last week. He joins PharmAthene from Gene Logic, where he directed alliances with pharmaceutical companies. PharmAthene works on preventing and treating diseases associated with biological warfare.

Gregory Sloma has been appointed to the board of directors of Transgenomic, the company said this week. He is currently executive vice president and CFO of “a privately held electronic communications company,” according to Transgenomic.

Eric Topol has joined the scientific advisory board of Perlegen, the company said last week. He is chief academic officer of The Cleveland Clinic Foundation and provost of the Cleveland Clinic Lerner College of Medicine of Case Western University.


Filed under

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.